aadibio.com - נכסים נקיים למניה בודדת WHWK

Aadi Bioscience Inc (WHWK) develops targeted therapies for rare tumors via its Nab platform and the drug Fyarro, establishing a unique niche in the treatment of mTOR-dependent cancers. The book value per share on this GURU.Markets chart reflects asset dynamics, where 3.24 determines the current metric. The operating model relies on GMP-standard manufacturing outsourcing through external partners.

For Aadi Bioscience Inc (WHWK), the book value per share serves as an indicator of the residual value of net assets, which is critical when clinical programs are scaled back and pipeline prospects are limited. The current value of 3.24, reflected through the calculated book value per share, demonstrates the company's fundamental basis; however, investors should consider the risk of capital impairment in the absence of stable cash flow.